Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 18/20 | 0.98 |
| ▸ | MAOA | P21397 | 2/20 | 0.82 |
| ▸ | MAOB | P27338 | 2/20 | 0.82 |
| ▸ | BCHE | P06276 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895981 | 1.00 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895985 | 1.00 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL5319124 | 0.92 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| SCHEMBL12043623 | 0.91 | ACHE (0.82) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL678895 | 0.90 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL3893996 | 0.90 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL3301711 | 0.90 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Fumaric Acid SCHEMBL3301186 | 0.87 | ACHE (0.74) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3300169 | 0.86 | ACHE (0.79) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3299550 | 0.86 | ACHE (0.79) | ACHEMAOAMAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140170208-A1 | TRANSDERMAL PATCH FORMULATION | LABTEC GMBH (DE) | 2014-06-19 | — | — | US | disclosed |
| US-20120265158-A1 | Transdermal Patch Formulation | LABTEC GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170208-A1 | TRANSDERMAL PATCH FORMULATION | CUTA, LPXN, TSLP | ACHE 66/4885MAOA 313/4885MAOB 827/4885 |
| US-20120265158-A1 | Transdermal Patch Formulation | CUTA, LPXN, TSLP | ACHE 66/4885MAOA 313/4885MAOB 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.